FDA greenlights a breakthrough against Alzheimer!

"Kisunla" is the name of the drug that works by targeting amyloid plaques in the brain, which are associated with Alzheimer's disease. The process aims to slow down the progression of memory and cognitive decline. The FDA's approval was based on a late-stage clinical trial involving 1,700 participants. Results showed that "Kisunla" slowed Alzheimer's progression by approximately 35% over 18 months compared to a placebo. This was measured using the clinical dementia rating scale, which evaluates six categories: memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care.